Please assess the completion status of the following clinical trial:

Trial Title: Docetaxel, 5-Fluorouracil and Oxaliplatin in Adenocarcinoma of the Stomach or Gastroesophageal Junction Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Histologically documented adenocarcinoma of the stomach or Gastroesophageal Junction (GEJ).~2. Age \>18 years;~3. Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1;~4. Chemotherapy: No prior chemotherapy is permitted for metastatic disease. Use of prior chemotherapy in the adjuvant and/or neo-adjuvant setting or as part of a radiosensitization is permitted, provided that the minimum time from completion of such treatment to study entry is at least 12 months;~5. Radiation: Patients may have had prior radiation therapy that has not exceeded 25% of bone marrow reserve provided that they have recovered from the acute, toxic effects of radiotherapy prior to registration. A minimum of 14 days must have elapsed since the end of radiotherapy.~6. Previous Surgery: Previous surgery is permitted provided that wound healing has occurred prior to registration. Minimum of 14 days must have elapsed between a major surgery and start of chemotherapy.~7. At least one target lesion \>20 mm (or \>10 mm on spiral CT-scan). If indicator lesions are in a previously irradiated field, only a clear disease progression of the irradiated lesion or a new lesion in the previously irradiated field will be accepted~8. Adequate baseline bone marrow, hepatic and renal function, defined as follows: Neutrophils \>1.5 \* 10\*9/L and platelets \>100 \* 10\*9/L; Bilirubin \<1.5 \* upper limit of the normal range (ULN); aspartate aminotransferase (AST or SGOT) and/or alanine aminotransferase (ALT or SGPT) \<2.5 \* ULN; Serum creatinine \<1.5 \* ULN;~9. Patients must give written informed consent to participate in the study.~10. Patients - both males and females - with reproductive potential (ie, menopausal for less than 1 year and not surgically sterilized) must practice effective contraceptive measures throughout the study. Women of child-bearing potential must have a negative pregnancy test (serum or urine) within 14 days prior to registration.~Exclusion Criteria:~1. Concurrent anticancer therapy~2. Pregnant or lactating women~3. History of other prior malignancy except for adequately treated basal cell or squamous cell skin cancer; in situ cervical cancer or malignancy from which the patient has been disease-free for 5 years;~4. Brain metastases~5. Patients with active or uncontrolled infections or with serious illnesses or medical conditions, including patients with a history of chronic alcohol abuse, hepatitis, HIV and/or cirrhosis~6. History of any psychiatric condition that might impair the patient's ability to understand or to comply with the requirements of the study or to provide informed consent.~7. Known hypersensitivity to any of the drugs.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 5-Fluorouracil + Docetaxel + Oxaliplatin (Type: EXPERIMENTAL): 5-Fluorouracil 2.2 Gm/m\^2 intravenously (IV) over 48 hours on Day 1. Docetaxel 20 mg/m\^2 IV over 60 minutes. Oxaliplatin 85 mg/m\^2 IV over 120 minutes on Day 1.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete